PROPHYLACTIC EFFICACY OF GLYCOSIDES RICH STANDARDIZED FENUGREEK SEED EXTRACT ON EXPERIMENTAL RENAL INTERSTITIAL FIBROSIS IN MICE
DOI:
https://doi.org/10.22159/ijpps.2025v17i12.56661Keywords:
Fenugreek, Glycosides, Renal interstitial fibrosis, Standardized extract, Unilateral ureteral obstructionAbstract
Objective: This study investigated the effects of glycosides-rich standardized fenugreek seed extract (SFSE-G) in a mouse model of “unilateral ureteral obstruction” (UUO)-induced renal fibrosis.
Methods: UUO was performed in 32 female mice (C57BL/6 strain) and randomized into groups of eight mice each. A separate group of eight mice (sham control) underwent sham operation with no UUO surgery. Mice were orally administered vehicle (distilled water) or SFSE-G at doses of 30, 60, or 100 mg/kg twice daily for 13 days. Various biochemical, histological, and gene expression-related measurements were conducted on day 14 after euthanasia, and body weights were measured daily.
Results: Subacute oral administration of SFSE-G showed dose-dependent significance (p<0.05, P<0.01) to reduce UUO-induced elevation of blood urea nitrogen levels and attenuated histopathological changes, including tubular injury and collagen deposition. Quantitative PCR revealed that SFSE-G downregulated oxidative stress-and fibrosis-related gene expression of markers such as “α-smooth muscle action”, “nuclear factor erythroid 2-related factor 2”, and “heme oxygenase-1”. Although SFSE-G-treated mice showed a downward trend against UUO-induced increases in hydroxyproline content and gene expression of “transforming growth factor-β1” and tissue inhibitor of collagen type 1 and metalloproteinase-1, the differences were not statistically significant.
Conclusion: SFSE-G exerts fibrosis preventive and renoprotective effects in UUO-induced renal fibrosis, probably by modulating oxidative stress and fibrotic pathways.
Downloads
References
1. Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines. Signal Transduct Target Ther. 2023;8(1):129. doi: 10.1038/s41392-023-01379-7, PMID 36932062.
2. Yan MT, Chao CT, Lin SH. Chronic kidney disease: strategies to retard progression. Int J Mol Sci. 2021;22(18):10084. doi: 10.3390/ijms221810084, PMID 34576247.
3. Antar SA, Ashour NA, Marawan ME, Al Karmalawy AA. Fibrosis: types, effects markers mechanisms for disease progression and its relation with oxidative stress immunity and inflammation. Int J Mol Sci. 2023;24(4):4004. doi: 10.3390/ijms24044004, PMID 36835428.
4. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013;3(2):957-76. doi: 10.1002/cphy.c120028, PMID 23720336.
5. Ma L, Liu D, Yu Y, Li Z, Wang Q. Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy. Front Immunol. 2025;16:1587806. doi: 10.3389/fimmu.2025.1587806, PMID 40534883.
6. Kalantar Zadeh K, Bellizzi V, Piccoli GB, Shi Y, Lim SK, Riaz S. Caring for patients with advanced chronic kidney disease: dietary options and conservative care instead of maintenance dialysis. J Ren Nutr. 2023;33(4):508-19. doi: 10.1053/j.jrn.2023.02.002, PMID 36796502.
7. Yaribeygi H, Simental Mendia LE, Butler AE, Sahebkar A. Protective effects of plant-derived natural products on renal complications. J Cell Physiol. 2019;234(8):12161-72. doi: 10.1002/jcp.27950, PMID 30536823.
8. Mohany M, Ahmed MM, Al Rejaie SS. Molecular mechanistic pathways targeted by natural antioxidants in the prevention and treatment of chronic kidney disease. Antioxidants (Basel). 2021;11(1):15. doi: 10.3390/antiox11010015, PMID 35052518.
9. Zhou Z, Qiao Y, Zhao Y, Chen X, Li J, Zhang H. Natural products: potential drugs for the treatment of renal fibrosis. Chin Med. 2022;17(1):98. doi: 10.1186/s13020-022-00646-z, PMID 35978370.
10. Fakhr L, Chehregosha F, Zarezadeh M, Chaboksafar M, Tarighat Esfanjani A. Effects of fenugreek supplementation on the components of metabolic syndrome: a systematic review and dose response meta-analysis of randomized clinical trials. Pharmacol Res. 2023;187:106594. doi: 10.1016/j.phrs.2022.106594, PMID 36470549.
11. Kim MJ, Sinam IS, Siddique Z, Jeon JH, Lee IK. The link between mitochondrial dysfunction and sarcopenia: an update focusing on the role of pyruvate dehydrogenase kinase 4. Diabetes Metab J. 2023;47(2):153-63. doi: 10.4093/dmj.2022.0305, PMID 36635027.
12. Laroubi A, Touhami M, Farouk L, Zrara I, Aboufatima R, Benharref A. Prophylaxis effect of Trigonella foenum graecum L. seeds on renal stone formation in rats. Phytother Res. 2007;21(10):921-5. doi: 10.1002/ptr.2190, PMID 17582593.
13. Ahsan SK, Tariq M, Ageel AM, Al Yahya MA, Shah AH. Effect of Trigonella foenum graecum and Ammi majus on calcium oxalate urolithiasis in rats. J Ethnopharmacol. 1989;26(3):249-54. doi: 10.1016/0378-8741(89)90097-4, PMID 2615405.
14. Kandhare AD, Bodhankar SL, Mohan V, Thakurdesai PA. Glycosides based standardized fenugreek seed extract ameliorates bleomycin induced liver fibrosis in rats via modulation of endogenous enzymes. J Pharm Bioallied Sci. 2017;9(3):185-94. doi: 10.4103/0975-7406.214688, PMID 28979073.
15. Kandhare AD, Bhaskaran S, Bodhankar SL. Potential of fenugreek in management of fibrotic disorders. In: Ghosh D, Thakurdesai P, editors. Fenugreek: traditional and modern medicinal uses. Boca Raton: CRC Press; 2022. p. 307-19. doi: 10.1201/9781003082767-23.
16. Kandhare AD, Bodhankar SL, Mohan V, Thakurdesai PA. Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-κB, Muc5ac, TNF-α and IL-1β. Chem Biol Interact. 2015;237:151-65. doi: 10.1016/j.cbi.2015.06.019, PMID 26093215.
17. Deshpande PO, Mohan V, Pore MP, Gumaste S, Thakurdesai PA. Prenatal developmental toxicity study of glycosides-based standardized fenugreek seed extract in rats. Pharmacogn Mag. 2017;13(49) Suppl 1:S135-41. doi: 10.4103/0973-1296.203978, PMID 28479738.
18. Deshpande P, Mohan V, Thakurdesai P. Preclinical safety assessment of glycosides-based standardized fenugreek seeds extract: acute subchronic toxicity and mutagenicity studies. J App Pharm Sci. 2016;6(9):179-88. doi: 10.7324/JAPS.2016.60927.
19. Norregaard R, Mutsaers HA, Frokiær J, Kwon TH. Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis. Physiol Rev. 2023;103(4):2827-72. doi: 10.1152/physrev.00027.2022, PMID 37440209.
20. Sunami R, Sugiyama H, Wang DH, Kobayashi M, Maeshima Y, Yamasaki Y. Acatalasemia sensitizes renal tubular epithelial cells to apoptosis and exacerbates renal fibrosis after unilateral ureteral obstruction. Am J Physiol Renal Physiol. 2004;286(6):F1030-8. doi: 10.1152/ajprenal.00266.2003, PMID 14722014.
21. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLOS One. 2016;11(6):e0158156. doi: 10.1371/journal.pone.0158156, PMID 27347680.
22. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76-85. doi: 10.1016/0003-2697(85)90442-7, PMID 3843705.
23. Panizo S, Martinez Arias L, Alonso Montes C, Cannata P, Martin Carro B, Fernandez Martin JL. Fibrosis in chronic kidney disease: pathogenesis and consequences. Int J Mol Sci. 2021;22(1):408. doi: 10.3390/ijms22010408, PMID 33401711.
24. Zhao HY, Li HY, Jin J, Jin JZ, Zhang LY, Xuan MY. L-carnitine treatment attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Korean J Intern Med. 2021;36 Suppl 1:S180-95. doi: 10.3904/kjim.2019.413, PMID 32942841.
25. Jiang YJ, Jin J, Nan QY, Ding J, Cui S, Xuan MY. Coenzyme Q10 attenuates renal fibrosis by inhibiting RIP1-RIP3-MLKL-mediated necroinflammation via Wnt3α/β-catenin/GSK-3β signaling in unilateral ureteral obstruction. Int Immunopharmacol. 2022;108:108868. doi: 10.1016/j.intimp.2022.108868, PMID 35636077.
26. Nawaz S, Chinnadurai R, Al Chalabi S, Evans P, Kalra PA, Syed AA. Obesity and chronic kidney disease: a current review. Obes Sci Pract. 2023;9(2):61-74. doi: 10.1002/osp4.629, PMID 37034567.
27. Rojas Canales DM, Li JY, Makuei L, Gleadle JM. Compensatory renal hypertrophy following nephrectomy: when and how. Nephrology (Carlton). 2019;24(12):1225-32. doi: 10.1111/nep.13578, PMID 30809888.
28. Shen R, Xu F, Liu L, Mao H, Ren J. Unilateral ureteral obstruction model for investigating kidney interstitial fibrosis. J Vis Exp. 2025;(218):e67897. doi: 10.3791/67897, PMID 40354230.
29. Hammad FT. The long-term renal effects of short periods of unilateral ureteral obstruction. Int J Physiol Pathophysiol Pharmacol. 2022;14(2):60-72. doi: 10.1186/s12967-017-1163-2, PMID 35619661.
30. Arifianto D, Adji D, Sutrisno B, Rickiawan N. Renal histopathology blood urea nitrogen and creatinine levels of rats with unilateral ureteral obstruction. IJVS. 2020;1(1):1-9. doi: 10.22146/ijvs.v1i1.55183.
31. Arifianto B, Rickyawan D. Interplay of renal histopathology blood urea nitrogen and creatinine levels in rats with unilateral ureteral obstruction: a comprehensive analysis. The American Journal of Veterinary Sciences and Wildlife Discovery. 2024;6(1):10-4. doi: 10.37547/tajvswd/Volume06Issue01-03.
32. Bulow RD, Boor P. Extracellular matrix in kidney fibrosis: more than just a scaffold. J Histochem Cytochem. 2019;67(9):643-61. doi: 10.1369/0022155419849388, PMID 31116062.
33. Schnaper HW. The tubulointerstitial pathophysiology of progressive kidney disease. Adv Chronic Kidney Dis. 2017;24(2):107-16. doi: 10.1053/j.ackd.2016.11.011, PMID 28284376.
34. Yakupova EI, Abramicheva PA, Bocharnikov AD, Andrianova NV, Plotnikov EY. Biomarkers of the end stage renal disease progression: beyond the GFR. Biochemistry (Mosc). 2023;88(10):1622-44. doi: 10.1134/S0006297923100164, PMID 38105029.
35. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75(11):1145-52. doi: 10.1038/ki.2009.86, PMID 19340094.
36. Martinez Klimova E, Aparicio Trejo OE, Tapia E, Pedraza Chaverri J. Unilateral ureteral obstruction as a model to investigate fibrosis attenuating treatments. Biomolecules. 2019;9(4):141. doi: 10.3390/biom9040141, PMID 30965656.
37. Hijmans RS, Rasmussen DG, Yazdani S, Navis G, Van Goor H, Karsdal MA. Urinary collagen degradation products as early markers of progressive renal fibrosis. J Transl Med. 2017;15(1):63. doi: 10.1186/s12967-017-1163-2, PMID 28320405.
38. La Russa A, Serra R, Faga T, Crugliano G, Bonelli A, Coppolino G. Kidney fibrosis and matrix metalloproteinases (MMPs). Front Biosci (Landmark Ed). 2024;29(5):192. doi: 10.31083/j.fbl2905192, PMID 38812325.
39. Uddin MJ, Kim EH, Hannan MA, Ha H. Pharmacotherapy against oxidative stress in chronic kidney disease: promising small molecule natural products targeting nrf2-ho-1 signaling. Antioxidants (Basel). 2021;10(2):258. doi: 10.3390/antiox10020258, PMID 33562389.
40. Grande MT, Lopez Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol. 2009;5(6):319-28. doi: 10.1038/nrneph.2009.74, PMID 19474827.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Prasad A Thakurdesai, Rohini Pujari
This work is licensed under a Creative Commons Attribution 4.0 International License.
